428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Karl Lewis; Ketty Peris; Aleksandar Sekulic; Alexander Stratigos; Lara Dunn; Zeynep Eroglu; Anne Lynn Chang; Michael Migden; Siyu Li; Kosalai Mohan; Ebony Coates; Emmanuel Okoye; Jean-François Baurain; Oliver Bechter; Axel Hauschild; Marcus Butler; Leonel Hernandez-Aya; Lisa Licitra; Rogerio Neves; Emily Ruiz; Frank Seebach; David Weinreich; George Yancopoulos; Israel Lowy; Timothy Bowler; Matthew Fury

doi:10.1136/jitc-2020-SITC2020.0428

Citation Tools

Regular and young investigator award abstracts

Clinical trials in progress

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Lewis K, Peris K, Sekulic A, et al

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0428

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password